These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6105188)

  • 1. Propranolol absorption in different regions of the rat gastrointestinal tract in situ: implications for sustained release formulations.
    Taylor DC; Grundy R
    J Pharm Pharmacol; 1980 Jul; 32(7):499-500. PubMed ID: 6105188
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition.
    Lo MW; Effeney DJ; Pond SM; Silber BM; Riegelman S
    J Pharmacol Exp Ther; 1982 May; 221(2):512-5. PubMed ID: 7077541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasal absorption of propranolol from different dosage forms by rats and dogs.
    Hussain A; Hirai S; Bawarshi R
    J Pharm Sci; 1980 Dec; 69(12):1411-3. PubMed ID: 7463327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings: An investigation of the rat in situ absorption model using practolol and propranolol.
    Taylor DC; Grundy RU
    J Pharm Pharmacol; 1975 Dec; 27 Suppl?-2():65P. PubMed ID: 2741
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Br J Clin Pharmacol; 1980 Jan; 9(1):33-40. PubMed ID: 7356891
    [No Abstract]   [Full Text] [Related]  

  • 7. Absorption of ipsapirone along the human gastrointestinal tract.
    Fuhr U; Staib AH; Harder S; Becker K; Liermann D; Schöllnhammer G; Roed IS
    Br J Clin Pharmacol; 1994 Jul; 38(1):83-6. PubMed ID: 7946942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of propranolol and 4-hydroxypropranolol using conventional and long-acting propranolol.
    Charles BG; Ravenscroft PJ; Renshaw PJ
    J Pharm Pharmacol; 1982 Jun; 34(6):403-4. PubMed ID: 6124628
    [No Abstract]   [Full Text] [Related]  

  • 9. Absorption of exaprolol from the in-situ gastrointestinal tract of rats and dogs.
    Motheová O; Zemánek M; Faberova V; Trnovec T; Gabauer I; Styk J; Durisová M; Nosálová V
    J Pharm Pharmacol; 1985 Nov; 37(11):816-9. PubMed ID: 2867165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats.
    Iwamoto K; Watanabe J
    J Pharm Pharmacol; 1985 Nov; 37(11):826-8. PubMed ID: 2867168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.
    Perucca E; Grimaldi R; Gatti G; Caravaggi M; Crema F; Lecchini S; Frigo GM
    Br J Clin Pharmacol; 1984 Jul; 18(1):37-43. PubMed ID: 6743489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets.
    Bechgaard H; Ladefoged K
    J Pharm Pharmacol; 1978 Nov; 30(11):690-2. PubMed ID: 31431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theoretical Michaelis-Menten elimination model for propranolol.
    McAinsh J; Gay MA
    Eur J Drug Metab Pharmacokinet; 1985; 10(3):241-5. PubMed ID: 4085525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between oral propranolol and hydralazine.
    McLean AJ; Skews H; Bobik A; Dudley FJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):726-32. PubMed ID: 7379440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition of propranolol. II. Hepatic elimination in the rat.
    Shand DG; Rangno RE; Evans GH
    Pharmacology; 1972; 8(4):344-52. PubMed ID: 4657981
    [No Abstract]   [Full Text] [Related]  

  • 18. [Theory and practice in design of gastrointestinal DDS].
    Nakano M
    Nihon Rinsho; 1989 Jun; 47(6):1249-54. PubMed ID: 2769986
    [No Abstract]   [Full Text] [Related]  

  • 19. Gastrointestinal clearance of drugs with activated charcoal.
    Levy G
    N Engl J Med; 1982 Sep; 307(11):676-8. PubMed ID: 7110218
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic study of a new sustained release preparation of propranolol in normal healthy volunteers.
    Biswas NR; Garg SK; Lal R; Kumar N; Gyawali K; Narendranath KA; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):436-8. PubMed ID: 3198297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.